Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention

Health Knowledge, Attitudes, Practice Clinical Trial

Official title:

Implementing Innovative and Strategic Approaches to Prevent and Mitigate the Deleterious Effects of HPV Across the Lifespan of Hispanics of Mexican Origin: Healthcare Provider Intervention

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05120869
• Other study ID #: 8321
• Secondary ID: 2U54MD007592-26
• Status: Recruiting
• Phase: N/A
• Start date: December 19, 2023
• Est. completion date: September 2024

Study information

• Verified date: February 2024
• Source: University of Texas, El Paso
• Contact: Kristin Gosselink, PhD
• Phone: 575-674-2335
• Email: kgosselink[@]burrell.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV). Our hypothesis is that improving provider knowledge and communication strategies about HPV and its vaccine will reduce hesitancy and increase uptake and completion among the populations they serve.

Description:

A sample of emerging [in training] and current [in practice] health professionals from the El Paso U.S.-Mexico Border Region will be recruited to participate in a human papillomavirus (HPV) educational and professional skills intervention. Hypothesis: improving provider knowledge and communication strategies about HPV and its vaccine will reduce hesitancy and increase uptake and completion among eligible individuals through a tailored multi-media intervention to strengthen providers' ability to discuss HPV and vaccination in an informed and culturally competent manner, and increase subsequent provider recommendations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: September 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Current (in practice) or emerging (in training - medical student, resident, or fellow) healthcare provider
• Working/training or living in the El Paso U.S.-Mexico Border Region (i.e., El Paso County, TX-Southern New Mexico)
• Have the authorization to recommend/prescribe/administer the HPV vaccine

Exclusion Criteria:

• Unaffiliated with the El Paso U.S.-Mexico Border Region (i.e., El Paso County, TX-Southern New Mexico)
• Participation in Phases I or II of the larger research project [cross-sectional phases]
• Does not identify as a current or emerging healthcare provider
• Declines or is unable to participate in the full intervention and follow-up time-points
• Unable to complete participation and activities in the English language

Related Conditions & MeSH terms

• Health Knowledge, Attitudes, Practice
• Health Personnel Attitude

Intervention

Behavioral:
• Tailored HPV Education and Professional Skills Intervention Group
The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
• General HPV Education and Communication Skills Control Group
The general provider education intervention will involve audio and visual content and will be delivered in the English language.

Locations

Country	Name	City	State
United States	The University of Texas at El Paso, Border Biomedical Research Center	El Paso	Texas
United States	Burrell College of Osteopathic Medicine	Las Cruces	New Mexico

Sponsors (3)

Lead Sponsor	Collaborator
University of Texas, El Paso	Burrell College of Osteopathic Medicine, National Institute on Minority Health and Health Disparities (NIMHD)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine. 2006 Apr 12;24(16):3087-94. doi: 10.1016/j.vaccine.2006.01.048. Epub 2006 Feb 9. — View Citation

Katz ML, Krieger JL, Roberto AJ. Human papillomavirus (HPV): college male's knowledge, perceived risk, sources of information, vaccine barriers and communication. J Mens Health. 2011 Oct 1;8(3):175-184. doi: 10.1016/j.jomh.2011.04.002. — View Citation

McRee AL, Brewer NT, Reiter PL, Gottlieb SL, Smith JS. The Carolina HPV immunization attitudes and beliefs scale (CHIAS): scale development and associations with intentions to vaccinate. Sex Transm Dis. 2010 Apr;37(4):234-9. doi: 10.1097/OLQ.0b013e3181c37e15. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Between-group changes in proportions from post-intervention scores of the Healthcare Provider (HCP) Practices scale on the Healthcare Personnel Survey	8-item HCP Practices scale (HCP vaccine recommendations, HCP screening recommendations, HCP communication practices) scored on a Likert scale from Never (1) to Always (5)	immediately post-intervention (0 months), 3 months post-intervention, and 6 months post-intervention
Secondary	Between-group changes in proportions from post-intervention scores of the Human Papillomavirus (HPV) Vaccine Attitudes scale on the Healthcare Personnel Survey	9-item HPV Vaccine Attitudes scale (perceived safety, perceived harm, perceived effectiveness) scored on a Likert scale from Strongly disagree (1) to Strongly agree (5)	immediately post-intervention (0 months), 3 months post-intervention, and 6 months post-intervention
Secondary	Between-group changes in proportions from post-intervention scores on the Human Papillomavirus (HPV) Knowledge scale on the Healthcare Personnel Survey	14-item HPV Knowledge scale scored as True (1) or False (0)	immediately post-intervention (0 months), 3 months post-intervention, and 6 months post-intervention

External Links

•   NIH RePORTER for 2U54MD007592-26 8321